Skip to NavigationSkip to content

AstraZeneca’s drug Lokelma approved in China

Published on 06/01/20 at 09:28am

AstraZeneca’s Lokelma has been approved by the National Medical Products Administration in China.

This is due to positive results based on its clinical trials as well as a pharmacodynamics study. These both showed that patients receiving the drug receive a sustained reduction of potassium in the blood.

Mene Pangalos, Executive Vice President for Biopharmaceuticals R&D at AstraZeneca, said: “This approval marks an important milestone for more than two million patients in China who suffer from hyperkalaemia. Lokelma will offer the opportunity for patients and physicians to achieve long-term disease control and potentially reduce the risk of acute episodes, which can have serious, even life-threatening consequences.”

Lokelma has previously been approved in some of the world’s biggest markets. The US, EU and Canada have already approved the drug, with it going through a separate regulatory review in Japan which is expected to be completed in early 2020.

Lokelma is used to treat hyperkalaemia. This condition is characterised by high levels of potassium in the blood and can be fatal, sometimes leading to cardiac arrest and death.

Symptoms include muscle weakness, numbness, tingling and nausea, with it usually developing slowly over weeks or months. Common causes can be a diet high in potassium or kidney disease. Sometimes it can be a side effect from medication that keeps the kidneys from removing enough potassium.

Conor Kavanagh

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches